Built From Early Alzheimer’s Biology, Expanded to Neurodegenerative Diseases
Alzheimer’s disease is biologically complex, involving multiple pathways that evolve years before dementia symptoms appear. Identifying the right blood-based pattern directly in humans would have required thousands of deeply characterized, longitudinal samples.
Instead, we pre-identified the most informative biomarkers on the first gene-transfer based animal model of the silent phase of Alzheimer's (Audrain et al., (2018) Cereb Cortex).This approach allowed us to discover new blood-based biomarkers linked to early disease biology.
These biomarkers were then validated in human cohorts, where they showed the ability to predict progression to Alzheimer’s dementia before symptoms become irreversible.
Today, AgenT quantifies 85 biomarkers from plasma and combines them with machine learning and longitudinal clinical follow-up to identify biological patterns linked to disease progression, patient stratification, and treatment development.
Although discovered in Alzheimer’s disease, these biomarkers map to 8 key biological pathways involved in neurodegeneration, making the platform relevant across multiple neurodegenerative diseases.